Huntington's Disease
86
5
9
62
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
26 trials with published results (30%)
Research Maturity
62 completed trials (72% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.6%
10 terminated out of 86 trials
86.1%
-0.4% vs benchmark
10%
9 trials in Phase 3/4
42%
26 of 62 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 62 completed trials
Clinical Trials (86)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD